Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can tracking lung nodules save lives? new study maps care in latin america

NCT ID NCT05091437

Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This completed study looked at how lung nodules are found and managed in hospitals across Latin America. Researchers tracked 562 adults to see how long it takes from finding a nodule to getting a diagnosis and treatment. The goal is to understand current practices and find ways to speed up early lung cancer detection.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could highlight gaps and opportunities in lung nodule management, potentially guiding policies to catch lung cancer earlier in Latin America.
What could go wrong
This is an observational study, not a treatment trial. It collects data but does not test any intervention, so it cannot directly improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

562 people

The number who actually took part.

Started

Dec 2021

Finished

Nov 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients (older than 35 years) who meet inclusion and exclusion criteria will be selected from the participants hospitals/clinics

Ages

35 to 100 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult subjects (≥ 35 years of age) * a) Prospective cohort: All eligible subjects with solid or subsolid (part solid, pure ground glass) lung nodule identified in imaging exams in routine clinical practice, prior to 30 days of informed consent given \[please refer to: Fleischner Society 2017 guidelines for nodules size and definition (≥ 6 mm and \< 3 cm)) for subject inclusion\]. Subjects identified from different sources (Nodules identified incidentally and in lung cancer screening programs) will be considered OR b) Retrospective cohort: All eligible subjects with solid or subsolid (part solid, pure ground glass) lung nodule identified in the past; more preciously from March 2019 to the study initiation date. \[Please refer to: Fleischner Society 2017 guidelines for nodules size and definition (≥ 6 mm and \< 3 cm) for subject inclusion\]. * Written informed consent to have medical data collected and stored for the prospective cohort and as guided by the local regulations for the retrospective cohort.. Exclusion Criteria: * Subjects unable to undergo any lung diagnostic procedure. * Individuals with a history of other malignancies are eligible if they have been disease-free for at least 5 years or are deemed by the investigator to be at low risk for recurrence of that malignancy * Subjects with calcified lung nodules with an established diagnosis

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

lung cancer Multiple Pulmonary Nodules

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pulmonary nodules

Contacts and locations

Locations

  • Research Site

    CABA, Argentina

  • Research Site

    Porto Alegre, Brazil

  • Research Site

    Rio de Janeiro, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    Antofagasta, Chile

  • Research Site

    Concepción, Chile

  • Research Site

    Bogotá, Colombia

  • Research Site

    Cundinamarca, Colombia

  • Research Site

    San José, Costa Rica

  • Research Site

    Santo Domingo, Dominican Republic

  • Research Site

    Monterrey, Nuevo León, Mexico

  • Research Site

    Estado de México, Mexico

  • Research Site

    Mexico City, Mexico

  • Research Site

    Panama City, Panama

More trials for these conditions

Other studies related to the condition(s) this trial covers.